Постменопаузальный метаболический синдром: пути коррекции дисбаланса вегетативной нервной системы комбинацией ингибитора АПФ и статина
И. В. Логачева, E. N. Shustova, E. V. Kulinich · Рациональная фармакотерапия в кардиологии · 2006
Aim. To study dynamics of the indices of heart rate variability (HRV) and heart remodeling in response on combined therapy with fosinopril and simvastatin in postmenopausal metabolic syndrome (MS). Material and methods. 95 women were dynamically examined (before and after 1 2 months of therapy with fosinopril and simvastatin) to assess heart rhythm variability (time and spectral domains) and remodeling with Holter ECG monitoring and echocardiography Results. Fosinopril has resulted in blood pressure decrease, reduction in heart remodeling and myocardial heterogeneity, which accompanied HRV rise with ncrease in parasympathetic activity. Simvastatin potentiated fosinopril positive effects on left ventricular hypertrophy, myocardial electric heterogeneity and autonomic modulation due to its prominent hypolipidemic and pleiotropic effect. Conclusion. In patients with postmenopausal MS medicines, which modified different elements of MS (ACE inhibitor and statin), not only have antihypertensive and hypolipidemic action, but also reduce the heart remodeling and improve the autonomic nervous system balance.
Cited by 0 works.